Please assess the completion status of the following clinical trial:

Trial Title: Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Philadelphia chromosome positive (Ph+) chronic phase chronic myelogenous leukemia (CML)~* Stratum I (closed to accrual as of 12/05/03):~  * CML in first chronic phase with resistance to interferon alfa (IFN-A) therapy defined as one of the following:~    * WBC count at least 20,000/mm\^3 after at least 3 months of treatment with an IFN-A-containing regimen~   * Rising WBC count (at least 100% increase to a level of at least 20,000/mm\^3) by two samples at least two weeks apart while receiving treatment with an IFN-A-containing regimen~   * At least 66% Ph+ cells in bone marrow after 1 year of IFN-A therapy~   * At least 30% increase in Ph+ cells in bone marrow after IFN-A-induced cytogenetic response while continuing to receive IFN-A therapy~ * Intolerance to interferon therapy defined as more than two grade 2 toxic effects or any grade 3 toxic effect related to interferon therapy, except grade 3 fever, that is persistent beyond the first 28-day course of therapy and unresponsive to standard supportive care interventions~* Stratum II (closed to accrual as of 7/29/05): CML recurring after stem cell transplantation or in second or subsequent chronic phase~  * No molecular relapse (only evidence is detection of bcr-abl rearrangement with normal bone marrow and blood morphology and normal standard cytogenetic analysis)~* Stratum III (closed to accrual as of 7/29/05): Newly diagnosed CML in first chronic phase with no prior treatment except hydroxyurea~* Stratum IV: Newly diagnosed CML in first chronic phase with no prior treatment except hydroxyurea~* No accelerated or blast phase defined as one or more of the following:~  * WBC doubling time less than 5 days~ * Chloroma~ * Medullary fibrosis~ * More than 10% blasts in peripheral blood or bone marrow~ * More than 20% promyelocytes in peripheral blood or bone marrow~ * More than 20% basophils and eosinophils in peripheral blood~* Performance status - ECOG 0-2~* At least 8 weeks~* See Disease Characteristics~* Shortening fraction ≥ 27% by echocardiogram OR ejection fraction ≥ 50% by radionuclide angiogram~* Bilirubin no greater than 1.5 times normal~* ALT less than 3.0 times normal~* Albumin greater than 2 g/dL~* Creatinine no greater than 1.5 times normal~* Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No uncontrolled infection~* No CNS toxicity greater than grade 2~* See Disease Characteristics~* No prior immunotherapy (for patients in stratum III \[closed to accrual as of 7/29/05\] and stratum IV only)~* At least 3 months since prior stem cell transplantation (SCT) (patients with allogeneic SCT must have no active graft-versus-host disease \[GVHD\] and have stable use of steroids) (for patients in stratum II only )~* At least 1 week since prior growth factors~* At least 1 week since prior biologic therapy, including interferon alfa (for patients in stratum I \[closed to accrual as of 12/05/03\] and stratum II only)~* Recovered from prior immunotherapy~* No concurrent immunomodulating agents~* See Disease Characteristics~* No prior chemotherapy (for patients in stratum III \[closed to accrual as of 7/29/05\] and stratum IV only)~* At least 6 weeks since prior busulfan or nitrosoureas~* At least 7 days since prior hydroxyurea~* At least 7 days since prior low-dose cytarabine (less than 30 mg/m\^2 every 12 to 24 hours)~* At least 14 days since prior moderate-dose cytarabine (100-200 mg/m\^2 for 5 to 7 days)~* At least 28 days since prior high-dose cytarabine (1-3 g/m\^2 every 12 to 24 hours for 6 to 12 doses)~* At least 21 days since all other cytotoxic chemotherapy~* Recovered from prior chemotherapy~* No concurrent chemotherapy~* No concurrent steroids other than for controlled GVHD in patients with prior allogeneic SCT~* No prior radiotherapy (for patients in stratum III \[closed to accrual as of 7/29/05\] and stratum IV only)~* At least 2 weeks since prior local palliative (small port) radiotherapy\*~* At least 3 months since prior craniospinal radiotherapy or radiotherapy to 50% or more of pelvis\*~* At least 6 weeks since prior substantial bone marrow radiotherapy\*~* Recovered from prior radiotherapy~* No prior imatinib mesylate~* No concurrent enzyme-activating anticonvulsants~* No concurrent warfarin~* No concurrent naturopathic agents or herbal medicines~* No other concurrent investigational agents~* Concurrent low-molecular weight heparin allowed

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (imatinib mesylate) (Type: EXPERIMENTAL): Patients receive oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who fail to achieve a complete hematologic response after 3 courses or a partial or complete cytogenic response after 6 courses are removed from the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).